The current study looked at almost 6,000 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database of men who had prostate cancer treated.

About 2,200 of the men involved -- 37 percent -- were receiving anticoagulants. The risk of death from prostate cancer was compared between those taking anti-coagulants and those who were not.

The study, published in the Journal of Clinical Oncology, demonstrated 10-year mortality from prostate cancer was 3 percent in the group taking anti-coagulants, compared to the 8 percent who didn't take anticoagulants. The risk of cancer recurrence and bone metastasis also were significantly lower, the study said.

However, further analysis suggested that this benefit was primarily derived from taking aspirin, as opposed to other types of anti-coagulants, Choe said.

"The results from this study suggest that aspirin prevents the growth of tumor cells in prostate cancer, especially in high-risk prostate cancer, for which we do not have a very good treatment currently," Choe said in a statement.

United Press International is a leading provider of news, photos and information to millions of readers around the globe via UPI.com and its licensing services.

With a history of reliable reporting dating back to 1907, today’s UPI is a credible source for the most important stories of the day, continually updated - a one-stop site for U.S. and world news, as well as entertainment, trends, science, health and stunning photography. UPI also provides insightful reports on key topics of geopolitical importance, including energy and security.

A Spanish version of the site reaches millions of readers in Latin America and beyond.

UPI was founded in 1907 by E.W. Scripps as the United Press (UP). It became known as UPI when after a merger with the International News Service in 1958, which was founded in 1909 by William Randolph Hearst. Today, UPI is owned by News World Communications.